Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Capricor has completed a Phase II trial in DMD that demonstrated potential functional benefits in ambulatory and non-ambulatory patients, and it has initiated follow-on studies to further characterize safety and efficacy. In addition, Capricor’s CAP-2003 program harnesses exosomes derived from CDCs to deliver bioactive molecules that may promote tissue repair, representing a next-generation approach to regenerative medicine.

Capricor serves patients throughout the United States and collaborates with academic and clinical research institutions to accelerate the translation of its therapies. The company’s research and development efforts are supported by strategic partnerships that provide access to specialized manufacturing, preclinical models, and clinical trial networks. Capricor’s leadership team is led by President and CEO Linda L. Marbán, PhD, who co-founded the company and has overseen its growth from an early-stage venture to a publicly traded biotech enterprise.

Key Stats

• Today's Range: $33.02 to $34.06
• 50-Day Range: $25.50 to $35.34
• 52-Week Range: $4.30 to $40.37
• Volume: 279,163 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $1.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.09
• Consensus Rating: Moderate Buy

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 546th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Capricor Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Capricor Therapeutics has a consensus price target of $46.09, representing about 37.8% upside from its current price of $33.46.

Amount of Analyst Coverage

Capricor Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Capricor Therapeutics are expected to decrease in the coming year, from $0.01 to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Capricor Therapeutics is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capricor Therapeutics is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.11% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 9.52.

Change versus previous month

Short interest in Capricor Therapeutics has recently increased by 1.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.38

News Sentiment

Capricor Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Capricor Therapeutics this week, compared to 10 articles on an average week.

Search Interest

Only 26 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

12 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,302,440.00 in company stock.

Percentage Held by Insiders

9.20% of the stock of Capricor Therapeutics is held by insiders.

Percentage Held by Institutions

21.68% of the stock of Capricor Therapeutics is held by institutions.

CAPR Stock Analysis - Frequently Asked Questions

How have CAPR shares performed this year?

Capricor Therapeutics' stock was trading at $28.86 at the start of the year. Since then, CAPR stock has increased by 15.9% and is now trading at $33.4550.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.11.
Read the conference call transcript.

Who are Capricor Therapeutics' major shareholders?

Top institutional shareholders of Capricor Therapeutics include Bank of New York Mellon Corp (0.23%), Swiss National Bank (0.17%), Patriot Financial Group Insurance Agency LLC (0.02%) and Pictet Asset Management Holding SA (0.01%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Anthony Bergmann, Karimah Es Sabar and Paul Gisbert Auwaerter.
View institutional ownership trends.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: 101
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Capricor Therapeutics: $46.09
• High Price Target: $63.00
• Low Price Target: $13.00
• Potential Upside/Downside: +39.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3,314.40
• P/E Growth: N/A
• Net Income: -$105.04 million
• Net Margins: N/A
• Pretax Margin: -736.58%
• Return on Equity: -67.52%
• Return on Assets: -54.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.01
• Quick Ratio: 9.01

Sales & Book Value

• Annual Sales: $22.27 million
• Price / Sales: 86.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.53 per share
• Price / Book: 5.99

Miscellaneous

• Outstanding Shares: 57,840,000
• Free Float: 52,519,000
• Market Cap: $1.92 billion
• Optionable: Optionable
• Beta: 0.48